Background
==========

Kidney transplantation for the management of end-stage renal disease (ESRD) is still the best approach that provides near-normal renal function, excellent survival outcomes and improved quality of life with lowest healthcare costs \[[@B1]\]. This picture is occasionally overshadowed by posttransplant thromboembolic events which negatively influence graft and patient survival. A hypercoagulable state early after transplanation may cause deep venous thrombosis and induces devastating complications like pulmonary embolism and death \[[@B2]-[@B4]\].

The description of Janus Kinase 2 (JAK2) gene at the short arm of chromosome 9, brought new insight into thromboembolic events. JAK2 encodes a cytoplasmic tyrosine kinase of growth factors and cytokines like erythropoietin, thrombopoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) and functions as a co-factor for cytokine responses in vivo and in cytokine mediated transduction pathways leading to cell proliferation. A recent single point mutation substituting phenylalanine for valine (V617F) of JAK2 has resulted with dysregulation of kinase activity and consequent overactive hematopoesis \[[@B5],[@B6]\]. Indeed, JAK2 V617F mutation frequently accompanied to chronic myeloproliferative disorders as polycythemia vera (PV) and essential thrombophilia (ET) in recent reports. Furthermore; patients with JAK2 V617F mutation have demonstrated recurrent episodes of venous thrombosis \[[@B5],[@B7],[@B8]\].

Splanchnic vein thrombosis (SVT) comprises extrahepatic portal vein, mesenteric vein and splenic vein thrombosis either alone or together and myeloproliferative diseases (MPD) are the most common etiologic factors \[[@B9]\]. Besides, JAK2 mutation has been accounted for the development of SVT, even in the absence of overt MPD \[[@B10]\]. Recent studies suggested JAK2 V617F mutation as a risk factor in the pathogenesis of SVT in general population \[[@B9],[@B11]\] albeit JAK2 gene mutation as a prothrombic risk factor in renal transplant recipients is yet to be defined.

Herein; we present a case of portosplenic vein thrombosis in a primary renal transplant recipient with JAK2 V617F mutation.

Case presentation
=================

A 59 year old female ESRD patient with unknown etiology,underwent a preemptive living donor kidney transplant from her son on the 6th April 2011. The donor and recipient B and T-cell crossmatch was negative. She has been followed at the Nephrology Unit of our institution since August 2006. She received induction immunosuppression with rabbit anti-human thymocyte globulin (ATG-Fresenius, 3-5 mg/kg/day) with prednisolone and mycophenolic acid, until serum creatinine (SCr) values reduced to 2.0 mg/dL. She had excellent initial function with a SCr:0.94 mg/dL at the 3rd day. Post-engraftment biopsy specimen demonstrated normal morphology of glomeruli and vascular structures with moderate (25-50%) acute tubular necrosis (Figure [1](#F1){ref-type="fig"}A). The maintenance immunosuppression consisted of prednisolon 30 mg/day and mycophenolic acid 900 mg/day. A calcineurin inhibitor or a proliferation signal inhibitor (PSI) drug was not administered within the first week of transplantation due to profound immunosuppression of ATG, being reflected by very low CD3 + T-cell count. Post-transplant recovery was complicated by acute graft dysfunction at day 7. Kidney biopsy revealed de novo thrombotic microangiopathy (TMA) with characteristic fibrin thrombi within the glomerular capillaries and arterioles and endothelial swelling. There was no interstitial infiltration but features of recovering acute tubular necrosis. Immunoflourescence staining showed intracapillary fibrin thrombi in the glomeruli. C4d deposition in peritubular capillaries (PTCs) was not present (Figure [1](#F1){ref-type="fig"}B). Hematological parameters, peripheral blood smear and coagulation tests were normal with no noteworthy changes within the last few days.

![**A: Post-engraftment biopsy (moderate acute tubular injury with otherwise normal architecture) (HE, ×200). B**: Thrombotic microangiopathy, acute tubular necrosis (HE, ×200).](1471-2369-14-161-1){#F1}

The patient was treated with pulse methylprednisolone, Double-filtration plasmapheresis (every other day for three times) and administration of intravenous immunoglobulins (total dose:2 mg/kg). She had completely recovered in two weeks with good graft function (SCr:1.0 mg/dL and eGFR via MDRD4: 61 mL/min/1.73 m^2^.) and discharged from the hospital with a maintenance immunosuppression including prednisolone 10 mg/day, mycophenolic acid 900 mg/day and everolimus 0.5 mg/day. Her routine follow-up was normal until the outpatient visit at 20 months after transplantation. She admitted with vague abdominal pain principally located at left upper quadrant. Abdominal ultrasound with color-doppler imaging demonstrated splenomegaly with hyperechoic trombi almost completely occluding splenic vein and portal vein upto portal hilum. The spleen was 150 mm. in longitudinal axis and there were multiple areas of nonvascularized segments both in liver and spleen. Intraabdominal ascites and deep vein thrombosis in lower limbs or in other abdominal organs were not present. These findings were confirmed by abdominal magnetic resonance imaging angiography.

She had no history of prior venous thromboembolism or identifiable thrombophilia. Liver and kidney function tests were completely normal and quantitative HCV-RNA with CMV, HBV and BK virus DNA PCR testing were negative. The only abnormal finding was increased platelet count (500--650 × 10^3^/mm^3^) in two consecutive measurements preceding the SVT. There was no evidence of portal hypertension or esophageal varices in upper gastroduodenal endoscopy. The laboratory assessement, prothrombic risk factors and clotting parameters are shown in Table [1](#T1){ref-type="table"}.

###### 

Laboratory data, genetic screening and bone marrow analysis

                                         **Value**          **Reference range**
  ---------------------------------- ----------------- -----------------------------
  WBC count, ×10^3^/mm^3^                   6.4                       
  Hgb level, g/L.                          13.2                       
  Haematocrit, %                           42.1                       
  Platelet count, ×10^3^/mm^3^              630                       
  **Peripheral blood smear**              **(%)**                     
  Neutrophils                               67                        
  Lymphocytes                               25                        
  Monocytes                                  6                        
  Eosinophils                                1                        
  Basophils                                  1                        
  **Thrombophilia parameters**            **(%)**                   (%)
  Antithrombin III (AT III)                115.5                  75-125
  Protein C (PC)                           98.4                   70-140
  Protein S (PS)                           87.2                   60-130
  Activated PC resistance (APCR)           0.36                  0.69-1.56
                                          (sec.)                      
  Lupus anticoagulant (LA)                 45.1                    31-34
  Lupus anticoagulant confirmation         36.5                    30-38
  **Genetic screening**               **(pos./neg.)**           **Comment**
  Factor V Leiden mutation               Positive           Heterozygot carrier
  BCR-ABL Mutation                       Negative                     
  prothrombin G20210A mutation           Negative                     
  JAK2 V617F mutation                    Positive                     
  **Bone marrow biopsy**                **YES/NO**                    
  Increased cellularity                     Yes                    (60%)
  Dyserythropoesis                          No                        
  Dysgranulopoesis                          No                        
  Megakaryocyte abnormality                 Yes             Dysplastic changes
  Clustering of megakaryocytes              Yes         Paratrabecular localization
  Haemophagocytosis                         No                        
  Fibrosis                                  No                        

The patient was diagnosed as SVT due to MPD (essential thrombocytosis, ET) with JAK2 V617F mutation. She was initially treated with enoxaparin 60 mg/0.6 mL. b.i.d for three days. She received enoxaparin with warfarin 2.5 mg/day for the following two days and switched to warfarin (≥5 mg/day) afterwards to achieve target INR values of 1.9-2.5. After 3 months of treatment, control MRI angiography and Doppler USG demonstrated partial (\>%50) resolution of thrombosis with recanalization of hepatopedal venous flow. (Figure [2](#F2){ref-type="fig"}A and B). There was no bleeding complication and the patient is still on the same treatment protocol.

![**A: MR imaging of portal vein thrombosis before anticoagulant treatment. B**: MRI of partial resolution of PV thrombus after warfarin treatment.](1471-2369-14-161-2){#F2}

Discussion
==========

The incidence of venous thromboembolism in renal transplant recipients, ranges between 0.6%-25% in the literature \[[@B2],[@B4],[@B12]\]. Many risk factors have been implicated in recurrent venous thrombosis or allograft thrombosis after renal transplantation. Among them; the presence of CMV infection and cyclosporine or rapamycine administration after transplantation are basically observations and the mechanism of thrombogenicity about these drugs and infection are not fully demonstrated in high-powered clinical trials \[[@B13]-[@B15]\]. In addition; pretransplant hypercoagulable states as vascular access thromboses, prior venous thromboembolism, essential thrombocytemia, ischemic heart disease on antiplatelet therapy, atrial fibrillation on vitamin K antagonist therapy, factor V Leiden and prothrombin G20210A mutation and the presence of antiphospholipid antibodies have all been defined as independant risk factors for renal allograft thrombosis but not for posttransplant SVT in patients with optimal graft function \[[@B13],[@B16],[@B17]\]. The impact of JAK2V617F mutation in the pathogenesis of splanchnic vein and peripheral venous thrombosis and thromboses in MPD has been disclosed in detail \[[@B5],[@B7],[@B8],[@B18]-[@B20]\]. A very interesting finding in patients with thrombotic complications was the high prevalence of this mutation in female patients with SVT, indicating a gender-related susceptibility, while it was uncommon in patients with venous thrombosis at other locations or with arterial thrombosis \[[@B18],[@B19]\]. There is strong clinical evidence that JAK2V617F mutation mediates overactivation of platelets in MPD \[[@B21],[@B22]\]. In one retrospective study including 241 cases of SVT, the JAK2V617F mutation was identified in 34% of MPD patients with portal vein thrombosis (PVT). Here, the investigators suggestted JAK2V617F mutation analysis as an initial test which should replace bone marrow investigations for MPD in patients with SVT \[[@B20]\]. In another series of 99 adult patients with SVT but without an overt MPD, 15% presented JAK2V617F mutation \[[@B23]\]. This finding was reproduced and substantiated in another study group in which this somatic mutation was present in 100% of patients with SVT and overt MPD and 41% of patients with SVT and latent MPD. Interestingly none of the patients with latent MPD have progressed to overt MPD more than 7 years of follow-up \[[@B24]\]. The frequent co-existence of MPD, SVT and JAK2V617F mutation has directed us towards genetic analysis in our patient. The differential diagnosis of SVT late after transplantation in a recipient with normal graft function requires exclusion of the aforementioned risk factors or conditions that frequently contribute to venous thrombosis in common or uncommon locations. As shown in Table [1](#T1){ref-type="table"}, this strategy is used in the present case. Factor V Leiden (G1691A) mutation was reported as a predisposing factor for thrombotic complications in renal transplant recipients. Genetic screening for protein C or S deficiency, antiphospholipid and anticardiolipin antibodies and G20210A prothrombin mutation were negative and JAK2V617F mutation was not studied in these patients \[[@B25]\].

The evaluation of etiology for SVT revealed JAK2V617F mutation accompanied by splenomegaly, thrombocytosis and bone marrow findings (megakaryocyte cellularity and clustering, presence of paratrabecular and dysplastic megakaryocytes without fibrosis) which indicates MPD, particularly essential thrombocytosis. The length of secondary prophylaxis after deep vein thrombosis (DVT) either by standard oral anticoagulation or by low molecular weight heparin is a matter of debate. In one study; 22 (46.8%) out of 47 patients with DVT experienced a recurrence after the withdrawal of antithrombotic treatment \[[@B2]\]. This high risk of recurrence in renal transplant patients should alert physicians for the administration of prolonged, probably life-long treatment, particularly to those with proven genetic susceptibility.

Conclusion
==========

To the best of our knowledge, this is the first case in the literature addressing the association between JAK2V617F mutation with MPD manifested by splanchnic vein thrombosis in a kidney transplant patient. This genetic study should be considered in kidney transplant patients with thrombosis in uncommon sites.
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